HR Execs on the Move

Surrozen

www.surrozen.com

 
Surrozen is a biotechnology company focused on discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.surrozen.com
  • 171 Oyster Point Blvd Suite 400
    South San Francisco, CA USA 94080
  • Phone: 650.475.2820

Executives

Name Title Contact Details
Elizabeth Nguyen
Vice President and Head of Human Resources Profile

Similar Companies

Labo America Inc

Labo America Inc is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Covance Labs

Covance Labs is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Syantra

With a cancer diagnosis, early detection means better outcomes. It means hope. But when it comes to breast cancer, more than half of women have a reduced opportunity for an early, life-saving diagnosis. That`s why we`re developing Syantra DX: a blood test to detect breast cancer. It`s a revolutionary, rapid, economical approach to breast cancer screening that`s accurate regardless of the test recipient`s family history, age or tissue density.

Odonate

Odonate Therapeutics™ is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered taxane. We are conducting our multinational, multicenter, randomized, Phase 3 study in locally advanced or metastatic breast cancer (MBC), known as CONTESSA. Our goal is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.

3-V Biosciences

3-V Biosciences, Inc. is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company`s lead candidate is a first-in-class, oral fatty acid synthase (FASN) inhibitor in Phase 1 clinical development that has been shown to block tumor cell signaling pathways and induce tumor cell apoptosis. 3-V`s antiviral therapeutics have demonstrated the ability to block host-pathogen interactions, resulting in robust and broad-spectrum in vitro and in vivo antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging internal expertise in biology, medicinal chemistry, drug discovery and development to drive programs forward. The company is located in Menlo Park, California.